Adverum Biotechnologies Inc. (NASDAQ: ADVM)
$8.80
-0.1200 ( -1.35% ) 2.1M
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
Market Data
Open
$8.80
Previous close
$8.92
Volume
2.1M
Market cap
$182.25M
Day range
$6.92 - $11.79
52 week range
$6.38 - $29.70
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 2 | Jun 20, 2024 |
4 | Insider transactions | 1 | Jun 20, 2024 |
4 | Insider transactions | 2 | Jun 20, 2024 |
4 | Insider transactions | 2 | Jun 20, 2024 |
4 | Insider transactions | 2 | Jun 20, 2024 |
4 | Insider transactions | 2 | Jun 20, 2024 |
4 | Insider transactions | 2 | Jun 20, 2024 |
4 | Insider transactions | 2 | Jun 20, 2024 |
3 | Insider transactions | 2 | Jun 20, 2024 |
4 | Insider transactions | 2 | Jun 20, 2024 |